U.K. pharmaceutical giant AstraZeneca is reportedly discussing a potential $400 billion merger with U.S. competitor Bristol Myers Squibb, a deal that would be one of the largest in history, according to the Financial Times.
Der britische Pharmakonzern AstraZeneca prüft laut einem Zeitungsbericht eine Fusion mit dem US-Konkurrenten Bristol Myers Squibb. Die Gespräche könnten zu einem der größten Pharmakonzerne weltweit führen, aber auch scheitern.
Bristol Myers Squibb partners with Hengrui Pharma to develop 12 experimental drugs, marking a significant, reciprocal collaboration that could signal increased U.S. pharmaceutical development in China for faster, cheaper drug creation.
Jiangsu Hengrui Pharmaceutical, China’s largest drug company by market capitalisation, has signed a global collaboration and licensing agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) worth up to US$15.2 billion. Hengrui’s Hong Kong-traded shares climbed 5.3 per cent to HK$69.55 on Tuesday, while its Shenzhen stock rose 4.84 per cent to 56.11 yuan. The deal adds credibility to China’s growing reputation for innovative drug development. Industry players, however, said the country...
